MHRA backing for Alyftrek for cystic fibrosis

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine deutivacaftor/tezacaftor/vanzacaftor) to treat cystic fibrosis (CF) in people aged six years and older who have specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been shown in trials to respond to the therapy.

This includes F508del, which is the most common cystic fibrosis causing mutation.

The new marketing authorization was granted via a national route to Vertex Pharmaceuticals (Nasdaq: VRTX).